Live Chat ×
Skip to main content

Biomarker Driven Lipidomics in Pharma R&D

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Paul Baker, Ph.D.

    Paul Baker received his PhD in Biochemistry from Wake Forest University School of Medicine. He did his post-doctoral work at the University of Alabama at Birmingham where he helped lead the discovery of a novel class of anti-inflammatory lipid mediators—nitrated lipids. He continued to work on nitrated lipids as an assistant professor at the University of Pittsburgh School of Medicine until June of 2011 when he joined SCIEX, where as a senior applications manager and the global lead scientist for Lipidomics, he pioneered the use of differential Ion mobility spectrometry in the study of lipids. In May of 2018, Paul joined Avanti Polar Lipids as the Analytical Division Director where he focused on developing new analytical and internal standard strategies for lipid analysis. Paul rejoined SCIEX in 2020 where he is now an advanced workflows specialist for Omics research by mass spectrometry with niche expertise in lipid analysis.

  • Kim Ekroos, Ph.D.

    Dr Kim Ekroos is the founder and CEO of Lipidomics Consulting Ltd. He received his Ph.D. degree in biology from the Technical University in Dresden, Germany, in 2003. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose. He is one of the pioneers in the field of lipidomics, with more than 20 years of experience in the academic, industry and regulatory disciplines of lipidomics. He is a co-founder of the Lipidomics Standards Initiative (LSI) and the president of the International Lipidomics Society.

  • Dayanjan (Shanaka) Wijesinghe, Ph.D.

    Dayanjan (Shanaka) Wijesinghe received his PhD in Biochemistry and Molecular Biology from Virginia Commonwealth University (VCU) School of Medicine. His thesis work involved the investigation of bioactive sphingolipids, the kinetics of their biosynthetic enzymes and their quantitation in various biological fluids and cell models using mass spectrometry. He continued this work into his postdoctoral training investigating the role of sphingolipids in human dermal wound healing, specifically their contribution to delayed healing. Following his postdoctoral studies, he joined VCU as the assistant director of the VCU lipidomics/metabolomics core facility before joining VCU School of Pharmacy as an assistant professor for clinical and translational research in 2015. Since then his laboratory has been actively investigating the role of lipids in the onset and resolution of human disease. The diseases currently under investigation include cardiac arrest, heart failure, sickle cell disease, polycystic ovary syndrome, chronic kidney disease, traumatic brain injury, aging as well as age related lipid metabolism abnormalities of HIV positive patients undergoing antiretroviral therapies. His laboratory employs both investigational and targeted mass spectrometry-based approaches for these studies. Additionally, the laboratory is also actively developing automated machine intelligence-based approaches for analysis and interpretation of lipidomic data.

May 21, 2020
Thu 12:30 PM EDT

Duration 1H 30M

This live web event has ended.